UCB (OTCMKTS:UCBJF) Price Target Cut to €86.00 by Analysts at Credit Suisse Group

UCB (OTCMKTS:UCBJFGet Rating) had its price target reduced by Credit Suisse Group from €90.00 ($92.78) to €86.00 ($88.66) in a research report released on Monday, The Fly reports.

Several other research analysts have also issued reports on UCBJF. Jefferies Financial Group lowered UCB from a buy rating to a hold rating in a report on Monday, July 25th. Barclays decreased their target price on shares of UCB from €110.00 ($113.40) to €90.00 ($92.78) in a research report on Tuesday, June 7th. Berenberg Bank decreased their price objective on UCB from €120.00 ($123.71) to €111.00 ($114.43) and set a buy rating for the company in a report on Friday, July 15th. Deutsche Bank Aktiengesellschaft reissued a hold rating and issued a $95.00 price target on shares of UCB in a research report on Friday, May 13th. Finally, Morgan Stanley reduced their target price on shares of UCB from €110.00 ($113.40) to €105.00 ($108.25) in a research note on Friday, July 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $105.25.

UCB Price Performance

UCBJF opened at $85.60 on Monday. The company has a fifty day moving average price of $88.62 and a two-hundred day moving average price of $102.14. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.25. UCB has a 1-year low of $85.60 and a 1-year high of $122.90.

About UCB

(Get Rating)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Read More

The Fly logo

Analyst Recommendations for UCB (OTCMKTS:UCBJF)

Want More Great Investing Ideas?

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.